Hepatitis B virus precore G1896A mutation in chronic liver disease patients with HBeAg negative serology from North India

Abstract EN

Hepatitis B with precore stop codon mutation is related with severe liver damage in HBeAg negative patients.

It is of utmost importance to screen the G1896A precore mutation.

The study was designed to assess the impact of G1986A mutations in patients with different clinical spectra of the liver disease by PCR–LCR.

210 HBV positive patients with HBeAg negative serology of different kind of liver diseases (AVH =72, FH =21, CH = 79, Cirrhosis = 20 and HCC = 18) were screened.

Patients were screened for the presence or absence of precore G1896A mutation by PCR–LCR.

Direct nucleotide sequencing was done to confirm the results of LCR.

Precore mutant in HCC was 94.4% (17/18), 85.7% (18/21) in FH, 60% (12/20) in liver cirrhosis, 48.1% (38/79) in chronic hepatitis and 27.7% (20/72) in AVH cases.

The serum ALT level was statistically significant between HBeAg negative WT and G1896A mutants in chronic hepatitis cases.

ALT level and HBV DNA level was slightly raised in the pre core mutant but and was not significant.

Genotype D had a higher prevalence (79.5%) as compared to genotype A (20.5%).

The mutations detected by PCR– LCR were in 100% concordance with direct sequencing.

The exceptionally high prevalence of G1896A in FH and HCC demonstrates that the precore mutants are strongly associated with the progression of liver diseases in patients with HBeAg negative serology.

The findings are also suggestive of screening HBV precore G1896A mutation particularly in HBeAg negative cases.

The precore G1896A mutation increases proportionately in severe form of liver diseases.

LCR can be a suitable tool for screening of G1896A mutations